MARKET

TOVX

TOVX

THERIVA BIOLOGICS INC
AMEX
0.2400
-0.0052
-2.12%
After Hours: 0.2490 +0.009 +3.75% 19:36 06/21 EDT
OPEN
0.2420
PREV CLOSE
0.2452
HIGH
0.2577
LOW
0.2400
VOLUME
143.32K
TURNOVER
0
52 WEEK HIGH
1.200
52 WEEK LOW
0.1972
MARKET CAP
4.15M
P/E (TTM)
-0.2084
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TOVX last week (0610-0614)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. Trinity Biotech stock rose 20.61% and Akari Therapeutics shares moved upwards by 20.26%. The company's Q1 earnings report came out today.
Benzinga · 06/11 16:31
12 Health Care Stocks Moving In Monday's After-Market Session
Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. LifeMD stock rose 5.81% in the same period. Losers Vicarious Surgical (NYSE:RBOT) and ProKidney stock fell 15.6% during the session.
Benzinga · 06/10 20:31
Weekly Report: what happened at TOVX last week (0603-0607)?
Weekly Report · 06/10 09:45
12 Health Care Stocks Moving In Wednesday's After-Market Session
Anitra shares increased by 6.5% to $0.18 during Wednesday's after-market session. PACS Group (NYSE:PACS) shares rose 3.95% during the session. Oragenics (AMEX:OGEN) shares moved upwards by 4.24%. Losers include Concord Medical Services and Theriva Biologics.
Benzinga · 06/05 20:31
Weekly Report: what happened at TOVX last week (0527-0531)?
Weekly Report · 06/03 09:46
Weekly Report: what happened at TOVX last week (0520-0524)?
Weekly Report · 05/27 09:47
Theriva gets FDA fast track status for VCN-01 for pancreatic cancer
Healthcare Theriva gets FDA fast track status for VCN-01 for pancreatic cancer. Theriva Biologics, Inc. Said it has received FDA fast-track designation for its drug VCn-01 in the treatment of metastatic pancreatic Cancer. The status was granted for the drug's use in combination with gemcitabine.
Seeking Alpha · 05/23 14:27
More
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Webull offers Theriva Biologics Inc stock information, including AMEX: TOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TOVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TOVX stock methods without spending real money on the virtual paper trading platform.